ArticleBritish journal of cancer2017

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.

Rastislav Bahleda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.